We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Effectiveness of PD-L1 Tests Compared for Non-Small-Cell Lung Cancer

By LabMedica International staff writers
Posted on 04 Oct 2016
Print article
Image: Average scores for tumor cells in study comparing results of four available PD-L1 assays used by pathologists in assessing non-small cell lung cancer tumors (Image courtesy of David Rimm Laboratory / Yale Cancer Center).
Image: Average scores for tumor cells in study comparing results of four available PD-L1 assays used by pathologists in assessing non-small cell lung cancer tumors (Image courtesy of David Rimm Laboratory / Yale Cancer Center).
In a recent study, clinical researchers compared performance of the 4 available assays for the tumor-promoting protein PD-L1 as a biomarker for assessing non-small cell lung cancer (NSCLC). They found that one assay failed to result in comparable levels of PD-L1, while the three other assays resulted in comparable levels.

The assays are used to test expression of PD-L1 on a patient’s tumor to help customize treatment options using drugs that may be more effective against lung cancer than chemotherapy. Findings of the new study were presented September 26, 2016, by researchers from Yale Cancer Center (New Haven, CT, USA) at the International Association for the Study of Lung Cancer (IASLC) 2016 Chicago Multidisciplinary Symposium in Thoracic Oncology (Chicago, USA). The study was sponsored by Bristol Myers Squibb with the National Comprehensive Cancer Network (NCCN) Oncology Research Program.

The team reviewed 90 surgically resected NSCLC cases (stages I-III) and sent a sample of each to four facilities for staining. A group of 13 pathologists at 7 institutions then reviewed the samples, using 4 different assays on each case, and scored them using a unified scoring system. A comprehensive statistical analysis was then performed on the scores collected.

Currently available are four drugs with four PD-L1 assays: 22c3, 28-8, E1L3N, and SP142. However only the 22c3 test is required by the US Food & Drug Administration (FDA) for prescription of a targeted anti-PD-1 drug (pembrolizumab), while the other tests are not yet required for prescription of other PD-1 axis drugs. The study revealed that SP142 systematically returned statistically lower levels of PD-L1 expression than the other three tests. This was true in both tumor and immune cells using any test. The other three available assays (28-8, E1L3N, and 22c3) showed no significant difference between them.

“Our data shows that the SP142 assay shows significantly lower levels of PD-L1 expression. This observation may limit the use of this assay in PD-L1 testing moving forward,” said first author David L. Rimm, MD, PhD, professor at Yale School of Medicine, “However, the other three assays seem equivalent, which is good news for the future when other PD-1 axis drugs with assay-specific diagnostics gain FDA approval.”

Related Links:
Yale Cancer Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.